Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sclerostin antibody
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Sclerostin antibodies (anti-sclerostin antibodies) are a class of monoclonal antibodies designed to target and inhibit sclerostin (SOST), a glycoprotein primarily secreted by osteocytes. Sclerostin acts as an endogenous antagonist of the canonical Wnt/β-catenin signaling pathway by binding to LRP5/6 co-receptors on osteoblasts, thereby suppressing bone formation. By neutralizing sclerostin, these antibodies restore Wnt signaling, which stimulates osteoblast activity and promotes bone formation (anabolic effect) while simultaneously reducing bone resorption (anti-catabolic effect). This dual mechanism of action makes sclerostin antibodies highly effective therapeutic candidates for bone-loss disorders, such as postmenopausal osteoporosis and osteogenesis imperfecta (OI). Prominent clinical-stage and approved agents in this class include romosozumab, blosozumab, and setrusumab.
- Other names
- Scl-AbSclAbSOST antibodyanti-SOST antibodyanti-sclerostin antibody
02
Targets
LRP5 (Low-density lipoprotein receptor-related protein 5)LRP6 (Low-density lipoprotein receptor-related protein 6)SOST (Sclerostin)
Beyond the preview
Go deeper on sclerostin antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sclerostin antibody.